Showing 1331-1340 of 9427 results for "".
Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeSummer AAD Highlights, Alopecia Areata Discovery
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-summer-aad-highlights-alopecia-areata-discovery/18846/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, new research that suggests emerging biologic therapies could help treat alopecia areata. Plus, updates on atopic dermatitis and eczema, hands-on education, and Kybella from the AAD Summer meeting. AndEpiduo Forte Approved; Facial Aesthetics By Age
https://practicaldermatology.com/topics/practice-management/dermwiretv-epiduo-forte-approved-facial-aesthetics-by-age/18870/Galderma's non-antibiotic Epiduo Forte (Adapalene 0.3% and benzoyl peroxide 2.5%) approved for topical management of acne vulgaris. Trends reveal differences in women's facial cosmetic surgery by age. AMA and CMS offer ICD-10 help. Plus: An Update on NewDerm LIVE.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.Alma Lasers Dye-PL Applicator for the HarmonyXL Platform
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/alma-lasers-dye-pl-applicator-for-the-harmonyxl-platform-/19243/Dye-PL is a new pulsed light applicator from Alma Lasers that concentrates the wavelength into a narrow filter of 100 nm, providing Dye Laser results, with the safety and efficiency of light.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvSaving for the High Cost of College: New Rule Offers Additional Options
https://practicaldermatology.com/issues/july-2025/saving-for-the-high-cost-of-college-new-rule-offers-additional-options/36511/Most Americans agree that money spent on higher education is critically important, as assets invested for this purpose can significantly influence the trajectory of a young person’s life.Research Highlights Disparities in AD Care
https://practicaldermatology.com/programs/practical-dermatology/research-highlights-disparities-in-ad-care/36472/In this episode of DermwireTV, research on socioeconomic disparities in atopic dermatitis care; new information on guselkumab for scalp psoriasis in diverse skin tones; the impact of air quality on dermatitis; and a C-Suite Chat with Anastasia Georgievskaya, founder of Haut.AI.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study